Incyte Corp (MIL:1INCY)
€ 66.84 0 (0%) Market Cap: 13.69 Bil Enterprise Value: 12.09 Bil PE Ratio: 541.07 PB Ratio: 4.61 GF Score: 70/100

Incyte Corp at UBS Global Healthcare Conference Transcript

May 20, 2019 / 07:00PM GMT
Carter Lewis Gould
UBS Investment Bank, Research Division - Large Cap Biotech Analyst

Okay. Good afternoon. My name is Carter Gould. I'm a senior biotech analyst here at UBS. Welcome to day 1 of the Global Healthcare Conference. I'm pleased to welcome Incyte to the stage. CEO and President, Hervé Hoppenot, is joining me. I also remind everyone if you'd like to ask questions through the app, please feel free. They will filter down to the iPad here and I will try to ask them. All right. Thank you very much for joining us.

HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO

© -

Thank you for inviting me.

Carter Lewis Gould
UBS Investment Bank, Research Division - Large Cap Biotech Analyst

I don't know if you want to make some opening statements or you just begin to...

HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO

© -

I could. Yes, if it's helpful -- I mean basically, the situation for Incyte today is based on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot